Quantum BioPharma Ltd. (NASDAQ: QNTM) was featured in a Men's Fitness article by Lakshan Weeraratne that examined clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article, which was highlighted in a press release distributed via NEWMEDIAWIRE, brings public attention to early-stage data that could influence how consumers and investors view the emerging alcohol recovery market.
The Men's Fitness piece focused on findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo. The article, available at the Men’s Fitness article by Lakshan Weeraratne, also emphasized the study's limitations, including its small sample size, company sponsorship and mixed results across broader measures of hangover severity and cognitive impairment.
While the findings suggest potential benefits for certain alcohol recovery measures, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive. That caveat is important for readers who might misinterpret the product's effects, and it underscores the difference between feeling more alert and being legally sober.
For investors, the Men's Fitness coverage represents a notable media validation for Quantum BioPharma, a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. The company's shares trade on Nasdaq under the ticker QNTM, and the press release directs investors to the company's newsroom at https://ibn.fm/QNTM for the latest updates. Quantum invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd, and the agreement includes royalty payments of 7% of sales until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The article's balanced presentation of the study's limitations may help temper expectations while keeping the door open for further research. The mixed results across broader measures of hangover severity and cognitive impairment suggest that Unbuzzd's effects are not uniform, and the small sample size means the findings are not statistically robust enough to draw definitive conclusions. Independent replication with larger groups will be necessary before the product can make strong claims.
For the industry, the coverage signals growing media and consumer interest in alcohol metabolism and recovery products, a category that has attracted attention as more people seek ways to moderate the aftereffects of drinking. However, the article's caution that increased alertness does not equal sobriety is a critical public-safety message that could shape how such products are marketed and regulated. As the company continues to develop its pipeline, including its lead compound Lucid-MS for multiple sclerosis, the Unbuzzd data will likely be watched closely by investors and researchers alike. Full terms of use and disclaimers are available at https://IBN.ai/Disclaimer.
